The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806.
Hui Kong Gan
No relevant relationships to disclose
Matthew E. Burge
No relevant relationships to disclose
Benjamin J. Solomon
No relevant relationships to disclose
Kyle D. Holen
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Yumin Zhang
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Marika Ciprotti
No relevant relationships to disclose
Thomas Merdan
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Wijith Munasinghe
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Michelle Pedersen
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Patricia F. Hintzman
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Gerard B. Fox
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Rod A. Humerickhouse
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Andrew Mark Scott
Consultant or Advisory Role - Life Science Pharmaceuticals